Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments (Q40712521)

23 September 2017

Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments (English)

1 reference

23 September 2017

Dan Lu

1

1 reference

23 September 2017

Xenia Jimenez

2

1 reference

23 September 2017

Haifan Zhang

3

1 reference

23 September 2017

Peter Bohlen

4

1 reference

23 September 2017

Larry Witte

5

1 reference

23 September 2017

Zhenping Zhu

6

1 reference

23 September 2017

1 September 2002

1 reference

Journal of Immunological Methods

23 September 2017

1 reference

23 September 2017

267

1 reference

23 September 2017

2

1 reference

23 September 2017

213-226

1 reference

Bispecific antibodies as novel bioconjugates.

23 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900148-5

Bispecific human IgG by design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900148-5

Toward the production of bispecific antibody fragments for clinical applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900148-5

Design and production of novel tetravalent bispecific antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900148-5

Leucine zipper dimerized bivalent and bispecific scFv antibodies from a semi-synthetic antibody phage display library

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900148-5

Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900148-5

Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900148-5

"Diabodies": small bivalent and bispecific antibody fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900148-5

High volumetric yields of functional dimeric miniantibodies in Escherichia coli, using an optimized expression vector and high-cell-density fermentation under non-limited growth conditions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900148-5

Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900148-5

Identification of the residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900148-5

A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900148-5

An efficient route to human bispecific IgG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900148-5

The first constant domain (CH1 and CL) of an antibody used as heterodimerization domain for bispecific miniantibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900148-5

Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900148-5

New protein engineering approaches to multivalent and bispecific antibody fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900148-5

'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900148-5

Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900148-5

Introduction: bispecific antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900148-5

Bispecific monoclonal antibodies from hybrid hybridomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900148-5

Design and application of diabodies, triabodies and tetrabodies for cancer targeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900148-5

Immunotherapeutic perspective for bispecific antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900148-5

Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900148-5

Engineering linear F(ab')2 fragments for efficient production in Escherichia coli and enhanced antiproliferative activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900148-5

Engineering high affinity humanized anti-p185HER2/anti-CD3 bispecific F(ab')2 for efficient lysis of p185HER2 overexpressing tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900148-5

High level secretion of a humanized bispecific diabody from Escherichia coli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900148-5

Remodeling domain interfaces to enhance heterodimer formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900148-5

An efficient route to the production of an IgG-like bispecific antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900148-5

10.1016/S0022-1759(02)00148-5

7 January 2021

Identifiers

DOI

1 reference

23 September 2017

1 reference